Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

about

REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.

P2860

Q36778705-BBEDACB3-A713-4B41-86AA-AA831186399A Q38255277-404EE557-4AA9-464B-BA50-9A498C68A801

P2860

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

Item

http://www.wikidata.org/entity/Q47356408

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

@en

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

@nl

type

Item

label

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

@en

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

@nl

prefLabel

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

@en

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

@nl

P1476

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

@en

P2093

Giedrius Vanagas

http://www.w3.org/2001/XMLSchema#string

Zilvinas Padaiga

http://www.w3.org/2001/XMLSchema#string

P2860

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Committee opinion no. 467: human papillomavirus vaccination

Using healthcare claims data for outcomes research and pharmacoeconomic analyses.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.

Chapter 2: The burden of HPV-related cancers.

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases.

Long-term efficacy of human papillomavirus vaccination.

Model for assessing human papillomavirus vaccination strategies.

P304

406-411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1403494812455467

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229437210

http://www.w3.org/2001/XMLSchema#string

P698

22821227

http://www.w3.org/2001/XMLSchema#string

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

about

P2860

P2860

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698